Adial Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Adial Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Assets Ratio: Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 97% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 96% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 2,502% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 93% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
100%Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 97% of Healthcare companies in United States.
Tangible Net Worth Ratio
100%Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 96% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (8)
Adial Pharmaceuticals, Inc. made a loss over the last year. Adial Pharmaceuticals, Inc. owes $2.32 for every $1 it owns. Adial Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAdial Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-0.29Adial Pharmaceuticals, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$11 MThe total market value of all of Adial Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), smaller than 87% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
NegativeAdial Pharmaceuticals, Inc.'s net worth is negative ($38 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Return on equity (ROE)
-2011.6%Adial Pharmaceuticals, Inc. lost 2011.6% of its shareholders' money over the last year, lower than almost all Healthcare companies in United States.
Owes vs Owns
2.32×Adial Pharmaceuticals, Inc. owes $2.32 for every $1 it owns, so it owes more than it owns, higher than 97% of Healthcare companies in United States.
Dividend yield
NoneAdial Pharmaceuticals, Inc. does not currently pay a dividend.
Profit growth
LossAdial Pharmaceuticals, Inc. made a loss in each of the last two years.
Questions
What is Adial Pharmaceuticals, Inc.'s return on equity?
Adial Pharmaceuticals, Inc. lost 2011.6% of its shareholders' money over the last year, lower than almost all Healthcare companies in United States.
How much does Adial Pharmaceuticals, Inc. owe compared with what it owns?
Adial Pharmaceuticals, Inc. owes $2.32 for every $1 it owns, so it owes more than it owns, higher than 97% of Healthcare companies in United States.
Does Adial Pharmaceuticals, Inc. pay a dividend?
No. Adial Pharmaceuticals, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.